Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982693 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess Chelation Therapy in Critical Limb Ischemia
A Phase 3 study of Diabetes and Critical Limb Ischemia, sponsored by Mt. Sinai Medical Center, Miami.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03982693: Recruiting Phase 3 study of Diabetes and Critical Limb Ischemia, sponsored by Mt. Sinai Medical Center, Miami.
NCT03982693 is a Phase 3 study of Diabetes and Critical Limb Ischemia that is actively recruiting participants, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 50 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03982693, a Phase 3 study of Diabetes and Critical Limb Ischemia, is actively recruiting participants, sponsored by Mt. Sinai Medical Center, Miami.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
Primary Outcome
Major cardiovascular endpoints include: coronary revascularization, stroke, MI, death (all-cause), or major amputation
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Edetate Disodium
Study Locations (1)
Florida
- Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2025-07 |
| Phase | Phase 3 |
What NCT03982693 shows while recruiting
NCT03982693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03982693 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03982693 about?
NCT03982693 is a clinical study titled "Trial to Assess Chelation Therapy in Critical Limb Ischemia". TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
What is the current status of trial NCT03982693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2019-03-19. Estimated completion is 2025-07.
What conditions does trial NCT03982693 study?
This clinical trial studies the following conditions: Diabetes, Critical Limb Ischemia.
What interventions are being tested in trial NCT03982693?
The interventions under investigation include: Placebo (OTHER), Edetate Disodium (DRUG).
Who is sponsoring clinical trial NCT03982693?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03982693 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03982693's enrollment target sits among peer trials
50 249th of 338 higher than 85 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI